Suppr超能文献

用远距钴疗法进行肿瘤治疗的患者骨髓和性腺剂量估算(作者译)

[Estimate of the dose in the marrow and the gonads of patients undergoing neoplastic treatment with telecobalt therapy (author's transl)].

作者信息

Mombelli L, Inversini G, Conte L, Favarò L, Cinquepalmi N, Grasso A

出版信息

Radiol Med. 1981 Apr;67(4):235-42.

PMID:7313155
Abstract

Measurements of the doses were carried out on phantoms in order to determine the dose in the marrow and gonads of patients undergoing radio-therapeutic treatment with telecobalt therapy with fixed fields. On average, the dose in the marrow for each treatment resulted to be 2.35 Gy in the male and 5.8 Gy in the female whereas the dose in the gonads for each treatment was on average 0.41 Gy in the male and 0.029 Gy with the exclusion of castrating doses in the female. If one considers the number of patients treated in 1975 with telecobalt therapy with fields (269 men and 309 women) the contribution to the leukaemia dose and to the genetically significant dose can be estimated in approximate terms for the year 1975 in the province of Varese: 0.48 mSv/year and 2.5.10-3 mSv/year respectively. Taking into account the risk factors indicated in publication 26 of the ICRP it can be deduced that in the group of patients treated the expected increase in the number of cases of leukaemia and genetic effects will be 5 and 0.5 respectively.

摘要

为了确定接受固定野远距离钴治疗的放射治疗患者骨髓和性腺中的剂量,在体模上进行了剂量测量。平均而言,每次治疗男性骨髓中的剂量为2.35 Gy,女性为5.8 Gy,而每次治疗性腺中的剂量男性平均为0.41 Gy,女性排除去势剂量后平均为0.029 Gy。如果考虑1975年接受固定野远距离钴治疗的患者数量(269名男性和309名女性),则可以大致估算出1975年瓦雷泽省对白血病剂量和遗传显著剂量的贡献:分别为0.48 mSv/年和2.5×10⁻³ mSv/年。考虑到国际放射防护委员会第26号出版物中指出的风险因素,可以推断出在接受治疗的患者组中,白血病病例数和遗传效应的预期增加分别为5例和0.5例。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验